People · Operator
Named in public records as an officer, director or promoter · active 2008–2024 · Biotechnology, Other Health Care, Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Atreca, Inc. | — | Biotechnology | Series D+ | $222.2M | $5.2B | 2015 |
| Immune Design Corp. | — | Biotechnology | Series C | $144.6M | $2.0B | 2008 |
| Cell Design Labs, Inc. | — | Biotechnology | Series B | $26.9M | $158.8M | 2016 |
| Veracyte, Inc. | — | Other Health Care | Series A | $22.1M | $258.2M | 2010 |
| Cero Therapeutics Holdings, Inc. | — | Pharmaceuticals | Series A | $16.4M | $17.9M | 2024 |
| Groove Biopharma Corp | — | Other Health Care | Series A | $8.4M | $90.8M | 2010 |
Brian Atwood at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Brian Atwood on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Brook Byers | 2 | 13 |
| Fred Cohen | 2 | 12 |
| Brian G. Atwood | 2 | 8 |
| Steven Gillis | 1 | 23 |
| Beth Seidenberg | 1 | 15 |
| Thong Le | 1 | 12 |
| Chad Waite | 1 | 11 |
| Carl Weissman | 1 | 8 |
| Franklin Berger | 1 | 7 |
| Richard Klausner | 1 | 7 |
| Lindsay Rayle | 1 | 7 |
| Chris Ehrlich | 1 | 6 |
| David Schubert | 1 | 6 |
| Jonathan T. Lord | 1 | 5 |
| William Robinson | 1 | 5 |
| Jesse I. Treu | 1 | 5 |
| Evan Jones | 1 | 4 |
| Samuel D. Colella | 1 | 4 |
| Lawrence Steinman | 1 | 4 |
| Andrew Allen | 1 | 4 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.